Revised KH Criteria for Sotrovimab Therapy for Outpatients with Mild to Moderate COVID-19

As you are aware, the Department of Health and Human Services has placed sotrovimab on a state-administered allocation. The Ohio Department of Health will allocate supply weekly to hospitals and health systems based on case count and supply availability.

Kettering Health is constantly reviewing restrictions of COVID-19 treatments based on supply chain considerations, patient volume, and current literature.

Based on estimated allocation, current usage, and provider feedback, the Kettering Health Pharmacy and Therapeutics Committee (P&T) has approved changes to the sotrovimab restrictions for outpatient COVID Infusion Center use.

Below is a summary of changes:

1. Removed “Patient has not received a COVID monoclonal antibody within the last 6 months” due to resistance of omicron variant to previous mAb treatments.
2. All solid organ transplant patients may qualify regardless of timing of transplant.
   1. Sotrovimab is preferred due to drug interactions with new oral COVID therapies.
3. Removed “severe combined immunodeficiencies” to reduce confusion with other comorbidities
4. Simplified wording to promote efficient review of risk criteria

Changes to EPIC referral forms will be forthcoming. Please see attached order forms for complete list of requirements for COVID-19 monoclonal antibody use.